Alzamend Neuro, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Alzamend's Phase 1/2A clinical trial at Massachusetts General Hospital compared AL001 (novel organic lithium co-crystal) to lithium carbonate (Li2CO3) in 30 participants across five cohorts (healthy, bipolar, major depression, Alzheimer's, PTSD). AL001 showed trends of higher brain lithium concentration (geometric mean 4,020.64 ng/g vs. 3,476.94 ng/g for Li2CO3) and higher plasma-to-brain transfer rate (K1), but differences were not statistically significant, attributed to small sample size. Trial used 7T MRI imaging with dual-tuned lithium/proton coils and includes planned analysis of patient cohorts.
Why this rating
Early-stage Phase 1/2A data showing favorable but non-significant trends for lead candidate. At $9.6M market cap, any clinical validation is material; however, lack of statistical significance and early-stage nature limit immediate impact. Continuation of funded research supports valuation but doesn't prove efficacy.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.